Related Experiment Video
Updated: Aug 11, 2026

Platelet Adhesion and Aggregation Under Flow using Microfluidic Flow Cells
Published on: October 27, 2009
Effect of various agents on prostaglandin biosynthesis and the anti-aggregatory effect
Abstract:
In view of the supposed importance of prostacyclin (PGI2) and thromboxane A2 (TXA2) in coronary regulation and platelet aggregation, the hypothesis has been proposed that anti-anginal drugs might increase the blood supply to the heart not only by vasodilation and diminution of cardiac work but also by inhibition of formation of dissolution of platelet aggregates. Anti-anginal drugs. especially dipyridamole and nitroglycerin were investigated to establish whether they increase the biosynthesis or anti-platelet effect of PGI2 and inhibit TXA2 synthesis. In various in vitro models, dipyridamole showed an enhancement of PGI2 synthetase and cyclo-oxygenase activity and increased PGI2 release, whereas it had only a weak inhibiting effect on TXA2 synthesis. There was a stimulating effect on PGI2 formation by some other anti-anginal drugs. in contrast, nitroglycerin did not stimulate the biosynthesis of PGI2 in rabbits or guinea pigs, but strongly inhibited TXA2 formation in platelets. It showed an additional inhibiting effect on platelet aggregation and increased additively or more than additively the anti-platelet effect of small doses of PGI2 in ADP-induced platelet aggregation. A hypothesis is discussed in which the action of nitroglycerin could be brought about by a vasodilating effect, as well as by its anti-platelet action on reversible platelet aggregates.
More Related Videos
10:35Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation
Published on: December 26, 2017
07:36Analysis of Raw and Processed Cyperi Rhizoma Samples Using Liquid Chromatography-Tandem Mass Spectrometry in Rats with Primary Dysmenorrhea
Published on: December 23, 2022
Related Concept Videos
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Antibody Actions
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Agonism and Antagonism: Quantification
To quantify these effects, researchers use a dose-response curve, which provides valuable information about the potency and efficacy of a drug. Potency refers to...
Factors Affecting Protein-Drug Binding: Drug Interactions
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...